Safety and Efficacy of Turoctocog Alfa During Long-Term Treatment of Severe and Moderately Severe Haemophilia A
Status:
Completed
Trial end date:
2020-01-15
Target enrollment:
Participant gender:
Summary
This study is conducted in Europe, and North and South America. The aim of this study is to
provide additional documentation of the immunogenicity, and obtain additional clinical data,
of turoctocog alfa in the setting of normal clinical practise in patients previously treated
with a factor VIII agent (FVIII).